FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Offers Path Forward for Twirla NDA

The CDER Office of New Drugs suggests a way that Agile Therapeutics can proceed with its Twirla contraceptive patch that received a 2017 complete resp...

Medical Devices

Eximo Laser Cleared for Peripheral Artery Disease

FDA clears Eximo Medical 510(k) for the B-Laser Atherectomy System for treating peripheral artery disease.

Federal Register

Panel to Discuss Opioid Analgesic Sparing Outcomes

Federal Register notice: FDA announces an 11/15 Anesthetic and Analgesic Drug Products Advisory Committee meeting to discuss the assessment of opioid ...

Medical Devices

Class 1 Recall for Endologix Safety Notice

FDA classifies as a Class 1 recall an Endologix safety notice to healthcare professionals about its AFX Endovascular AAA System and the risks associat...

Human Drugs

Novartis NDA Accepted for Multiple Sclerosis Drug

FDA accepts for review a Novartis NDA for once-daily siponimod (BAF312) for treating secondary progressive multiple sclerosis in adults.

Human Drugs

FDA OKs Akcea Therapeutics/Ionis Pharmaceuticals Drug

FDA approves an Akcea Therapeutics and Ionis Pharmaceuticals NDA for Tegsedi (inotersen) for treating polyneuropathy of hereditary transthyretin-media...

Human Drugs

Karyopharm Therapeutics NDA for Multiple Myeloma

FDA accepts for priority review a Karyopharm Therapeutics NDA that is seeking accelerated approval for selinexor, an oral SINE compound indicated for ...

Human Drugs

FDA Tentatively Approves Orthos Psoriasis Lotion

FDA tentatively approves an Ortho Dermatologics NDA for Bryhali (halobetasol propionate) lotion for the topical treatment of plaque psoriasis in adult...

FDA General

Latest Federal Register Notices

FDA Review posts the Federal Register notices for the week ending 10/5/2018.

Federal Register

Joint Panel to Review Abuse-deterrent Pain Drug

Federal Register notice: FDA announces an 11/14 joint advisory committee meeting to discuss a SpecGx NDA for its abuse-deterrent pain drug.